The Food and Drug Administration this week approved the first interchangeable biosimilar insulin product to treat diabetes. The product (Semglee) can be substituted for the previously approved biological insulin product Lantus to treat type 1 diabetes in children and type 1 or 2 diabetes in adults.

“This is a momentous day for people who rely daily on insulin for treatment of diabetes, as biosimilar and interchangeable biosimilar products have the potential to greatly reduce health care costs,” said Acting FDA Commissioner Janet Woodcock, M.D. 
 
For more information on biosimilar and interchangeable products, see the new FDA resources for health care providers.
 

Related News Articles

Headline
The Centers for Medicare & Medicaid Services today approved Medicaid demonstrations for Oregon and Massachusetts that will test innovative approaches…
Headline
At a White House conference today on hunger, nutrition and health, the Biden Administration announced $8 billion in public- and private-sector commitments…
Headline
The recent paralytic polio case in an unvaccinated adult in Rockland County, N.Y. and wastewater samples from communities near the patient’s residence meet the…
Headline
The Centers for Medicare & Medicaid Services yesterday approved for Oregon the first Medicaid state plan amendment to cover community-based mobile crisis…
Headline
In this first podcast in a new AHA Advancing Health series, #JustLead, Shana Dacon-Pereira, senior director for the office of diversity and inclusion at Mount…
Headline
The Food and Drug Administration yesterday alerted health care providers and the public to reports of squamous cell carcinoma in scar tissue around breast…